2 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 2 Phase 1, 1 Not applicable, 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 1, Unknown 1 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow Hyperlipoproteinemia Type V: new trials by email Literature Review of Hyperlipoproteinemia Type V trials Research Report on Hyperlipoproteinemia Type V
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias CTX310 - Cardiovascular, Metabolic Disease | Phase 1 | Recruiting | CRISPR Therapeutics AG | 90 | 2024-06-21 | 2026-09-18 |
| Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management Alert - Hyperlipemia, Mixed, ASCVD | Not applicable | Active not recruiting | Brigham and Women's Hospital | 400 | 2021-10-08 | 2026-09-29 |
| Study to Evaluate the Safety and PK of UI018 administration of UI018, co-administration of UIC201806 and UIC201602 - Hyperlipemia, Mixed | Phase 1 | Unknown | Korea United Pharm. Inc. | 44 | 2021-09-06 | 2021-12-21 |
| Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage SHR-1209, SHR-1209 Placebo - Primary Hypercholesterolemia, Mixed Hyperlipemia | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 709 | 2021-04-23 | 2023-05-19 |
| Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients rosuvastatin - Hypertriglyceridemia, Hyperlipoproteinemia Type IV | Phase 4 | Completed | AstraZeneca | 334 | 2007-01-01 | 2010-12-16 |
| MK0859 Dose-Ranging Study (0859-003) MK0859 - Hypercholesterolemia, Mixed Hyperlipemia | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 500 | 2006-06-01 | 2015-03-02 |
Hypercholesterolemia (2) · Hyperlipidemias (2) · Hypertriglyceridemia (2) · Dyslipidemias (1) · Homozygous Familial Hypercholesterolemia (1) · Hyperlipoproteinemia Type II (1) · Hyperlipoproteinemia Type IV (1) · Hyperlipoproteinemias (1) · Lipid Metabolism Disorders (1) · Metabolic Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Lipid Metabolism, Inborn Errors (6) · Metabolism, Inborn Errors (6) · Nutritional and Metabolic Diseases (6) · Dyslipidemias (5) · Hyperlipoproteinemias (5) · Lipid Metabolism Disorders (5) · Metabolic Diseases (5) · Hyperlipidemias (4) · Hypertriglyceridemia (4) · Hyperlipoproteinemia Type II (1)
Caffeine (1) · Rosuvastatin Calcium (1) · anacetrapib (1)
AstraZeneca (1) · Brigham and Women's Hospital (1) · CRISPR Therapeutics AG (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Korea United Pharm. Inc. (1) · Merck Sharp & Dohme LLC (1)
United States (2) · Australia (1) · China (1) · Mexico (1) · New Zealand (1) · South Korea (1) · United Kingdom (1)
Ana Polanco, MD (1) · Injin Jang, Dr. (1) · Juan Talavera, MD (1)